2022 WGND Annual Meeting

November 3, 2022 | Zoom Webinar

Overview

The Stop TB Partnership Working Group on New Drugs’ Annual Meeting has proven valuable as a neutral forum to bring together those working in research and development to get a full understanding of the progress, challenges, and critical issues to developing TB treatment.

Speakers
Melvin Spigelman
TB Alliance, WGND
Barbara Laughon
NIH/NIAID, WGND
Zaid Tanvir
TB Alliance, WGND
Charles Wells
Gates Medical Research Institute
Martin Boeree
Pan-African Consortium for Evaluation of Anti-TB Antibiotics (PanACEA)
Kelly Dooley
AIDS Clinical Trials Group
Wendy Carr
US CDC TBTC
Nicholas Paton
SPRINT-TB
Carole Mitnick
Harvard Medical School
Todd Black
TB Alliance
Mischka Moodley
Otsuka
Alexander Pym
Janssen
Robert Bates
GlaxoSmithKline
Gustavo Velásquez
Norbert Heinrich
University of Munich
Meeting Recap

The 2022 WGND Annual Meeting took place on Thursday, November 3rd at 9AM EDT / 2PM CET / 6:30PM IST. During the meeting, updates were provided by representatives from pharmaceutical, government agencies, research organizations, non-profits, academia, and others involved in TB research and development. The meeting provided an overview of the current state of the Global TB Drug Pipeline with representatives providing updates on active trials, collaborations, novel compounds, and treatment research. 

The meeting was held using Zoom Webinar. Presentations and a recording of the meeting will be available in the coming days. Please check back here for their availability. 

  • Working Group on New Drugs Presentations
    TB Drug Development Year-in-Review
    Barbara Laughon
    https://www.newtbdrugs.org/sites/default/files/meetings/files/00_Barbara%20Laughon_2022.WGND_.Year%20in%20Review.pdf
    2022 WGND Updates
    Zaid Tanvir
    https://www.newtbdrugs.org/sites/default/files/meetings/files/01_Zaid%20Tanvir_WGND%20Update.pdf
  • TB Drug Development Updates
    Gates Medical Research Institute
    Charles Wells
    https://www.newtbdrugs.org/sites/default/files/meetings/files/02_Charles%20Wells_GMRI.pdf
    UNITE4TB
    Martin Boeree
    https://www.newtbdrugs.org/sites/default/files/meetings/files/03_Martin%20Boeree_UNITE4TB.pdf
    AIDS Clinical Trials Group
    Kelly Dooley
    https://www.newtbdrugs.org/sites/default/files/meetings/files/04_Kelly%20Dooley_ACTG.pdf
    US CDC Tuberculosis Trials Consortium
    Wendy Carr
    https://www.newtbdrugs.org/sites/default/files/meetings/files/05_Wendy%20Carr_US%20CDC%20TBTC.pdf
    TRUNCATE TB
    Nicholas Paton
    https://www.newtbdrugs.org/sites/default/files/meetings/files/06_Nick%20Paton_TRUNCATE-TB.pdf
    endTB / endTB-Q
    Carole Mitnick
    https://www.newtbdrugs.org/sites/default/files/meetings/files/07_Carole%20Mitnick_endTB_endTB-Q.pdf
    TB Alliance
    Todd Black
    https://www.newtbdrugs.org/sites/default/files/meetings/files/08_Todd%20Black_TB%20Alliance.pdf
    Otsuka
    Mischka Moodley
    https://www.newtbdrugs.org/sites/default/files/meetings/files/09_Mischka%20Moodley_Otsuka.pdf
    Janssen
    Alexander Pym
    https://www.newtbdrugs.org/sites/default/files/meetings/files/10_Alex%20Pym_Janssen.pdf
    GlaxoSmithKline
    Robert Bates
    https://www.newtbdrugs.org/sites/default/files/meetings/files/11_Rob%20Bates_GSK.pdf
    SMART4TB
    Gustavo Velásquez
    https://www.newtbdrugs.org/sites/default/files/meetings/files/12_Gustavo%20Velasquez_SMART4TB.pdf
    PanACEA / LMU Munich
    Martin Boeree
    Norbert Heinrich
    https://www.newtbdrugs.org/sites/default/files/meetings/files/13_Martin%20Boeree_PanACEA.pdf
    https://www.newtbdrugs.org/sites/default/files/meetings/files/13_Norbert%20Heinrich_LMU%20Munich.pdf